<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">0413066</journal-id>
<journal-id journal-id-type="pubmed-jr-id">2830</journal-id>
<journal-id journal-id-type="nlm-ta">Cell</journal-id>
<journal-id journal-id-type="iso-abbrev">Cell</journal-id>
<journal-title-group>
<journal-title>Cell</journal-title>
</journal-title-group>
<issn pub-type="ppub">0092-8674</issn>
<issn pub-type="epub">1097-4172</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28823556</article-id>
<article-id pub-id-type="pmc">5740873</article-id>
<article-id pub-id-type="doi">10.1016/j.cell.2017.07.033</article-id>
<article-id pub-id-type="manuscript">NIHMS912227</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Excess translation of epigenetic regulators contributes to Fragile X Syndrome and is alleviated by Brd4 inhibition</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Korb</surname>
<given-names>Erica</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Herre</surname>
<given-names>Margaret</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zucker-Scharff</surname>
<given-names>Ilana</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gresack</surname>
<given-names>Jodi</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Allis</surname>
<given-names>C. David</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="author-notes" rid="FN1">*</xref>
<xref ref-type="author-notes" rid="FN2">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Darnell</surname>
<given-names>Robert B.</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="author-notes" rid="FN1">*</xref>
</contrib>
</contrib-group>
<aff id="A1">
<label>1</label>Laboratory of Chromatin Biology and Epigenetics, The Rockefeller University, New York, NY 10065, USA</aff>
<aff id="A2">
<label>2</label>Laboratory of Molecular Neuro-oncology and Howard Hughes Medical Institute, The Rockefeller University, New York, NY 10065, USA</aff>
<aff id="A3">
<label>3</label>Laboratory of Molecular and Cellular Neuroscience, The Rockefeller University, New York, NY 10065, USA</aff>
<author-notes>
<corresp id="FN1"><label>*</label>Correspondence: <email>alliscd@rockefeller.edu</email>, <email>darnelr@rockefeller.edu</email></corresp>
<fn id="FN2">
<label>4</label>
<p>Lead contact</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>23</day>
<month>10</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>17</day>
<month>8</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="ppub">
<day>07</day>
<month>9</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>22</day>
<month>12</month>
<year>2017</year>
</pub-date>
<volume>170</volume>
<issue>6</issue>
<fpage>1209</fpage>
<lpage>1223.e20</lpage>
<!--elocation-id from pubmed: 10.1016/j.cell.2017.07.033-->
<abstract>
<title>SUMMARY</title>
<p id="P1">Fragile X Syndrome (FXS) is a leading genetic cause of intellectual disability and autism. FXS results from the loss of function of Fragile X Mental Retardation Protein (FMRP), which represses translation of target transcripts. Most of the well-characterized target transcripts of FMRP are synaptic proteins, yet targeting these proteins has not provided effective treatments. We examined a group of FMRP targets that encode transcriptional regulators, particularly chromatin-associated proteins. Loss of FMRP in mice results in widespread changes in chromatin regulation and aberrant gene expression. To determine if targeting epigenetic factors could reverse phenotypes associated with the disorder, we focused on Brd4, a BET protein and chromatin reader targeted by FMRP. Inhibition of Brd4 function alleviated many of the phenotypes associated with FXS. We conclude that loss of FMRP results in significant epigenetic misregulation and that targeting transcription via epigenetic regulators like Brd4 may provide new treatments for FXS.</p>
</abstract>
</article-meta>
</front>
</article>
</pmc-articleset>